Advanced Plant Pharmaceuticals, Inc. Announces Dr. Veronica Motiram as the Second Site for Lo-Chol Cholesterol Double Blind Study

NEW YORK, Feb. 17, 2004 (PRIMEZONE) -- Advanced Plant Pharmaceuticals, Inc. (APPI) (OTCBB:APPI), a company that utilizes whole plants through a proprietary (patent pending) manufacturing process to develop all-natural whole plant pharmaceuticals and nutritionals, has announced that it will enlarge the original CRL clinical study, by adding Dr. Veronica Motiram, of the Neuropsychiatric Center of the Palm Beaches, Boynton Beach, Florida as the second site.

Dr. Motiram will conduct a 12-month, randomized, placebo-controlled, cross-over study to evaluate the LDL/HDL cholesterol ratios of 30 patients treated with Lo-Chol(TM). A statistical analysis by a qualified bio-statistician at the four-month and eight-month stage will be compiled and reported to APPI to provide data for a peer-reviewed scientific journal article.

Lo-Chol(TM) is a unique, proprietary supplement that is produced utilizing APPI's patent pending "Whole Plant" process, which develops whole plant pharmaceuticals and nutritionals. Patients with high cholesterol who experience the worst of the documented side effects that many prescription cholesterol-lowering drugs cause often seek alternative, natural supplements such as Lo-Chol(TM).

About Dr. Veronica Motiram

Dr. Motiram has 20 years of field experience and is currently running clinical trials for all the major pharmaceutical companies in the USA at her office site in Florida. She is also a faculty member at the West Boca Medical Center in Boca Raton, Florida.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.